Amneal Pharmaceuticals (AMRX) Accounts Payables (2017 - 2026)
Amneal Pharmaceuticals has reported Accounts Payables over the past 9 years, most recently at $55.5 million for Q4 2025.
- For Q4 2025, Accounts Payables rose 2774150.0% year-over-year to $55.5 million; the TTM value through Dec 2025 reached $55.5 million, up 2774150.0%, while the annual FY2025 figure was $55.5 million, 2774150.0% up from the prior year.
- Accounts Payables for Q4 2025 was $55.5 million at Amneal Pharmaceuticals, down from $731.8 million in the prior quarter.
- Over five years, Accounts Payables peaked at $731.8 million in Q3 2025 and troughed at $2000.0 in Q4 2024.
- A 5-year average of $259.2 million and a median of $29.6 million in 2024 define the central range for Accounts Payables.
- Biggest five-year swings in Accounts Payables: tumbled 99.99% in 2023 and later soared 2774150.0% in 2025.
- Year by year, Accounts Payables stood at $525.3 million in 2021, then crashed by 99.99% to $72000.0 in 2022, then skyrocketed by 2619.44% to $2.0 million in 2023, then plummeted by 99.9% to $2000.0 in 2024, then soared by 2774150.0% to $55.5 million in 2025.
- Business Quant data shows Accounts Payables for AMRX at $55.5 million in Q4 2025, $731.8 million in Q3 2025, and $1.2 million in Q2 2025.